Iovance Biotherapeutics (IOVA) Q4 2025 earnings summary

Executive summary

• Achieved 30% quarterly revenue growth in Q4 2025 and 61% year-over-year for the full year, driven by strong AMTAGVI demand, operational improvements, and expanded ATC network.

• Full-year 2025 revenue reached $264 million, meeting annual guidance, with gross margin improving to 50% in Q4 due to operational efficiencies and internalized manufacturing.

• Advanced pipeline with lifileucel showing strong efficacy in non-small cell lung cancer and sarcoma, including FDA Fast Track designation and positive early/interim data.

• Extended cash runway into Q3 2027 through cost optimization, disciplined capital use, and a year-end cash position of $303 million.

• Amtagvi approved in Canada, with regulatory submissions underway in the UK, Australia, and Switzerland.

Financial highlights

• Q4 2025 product revenue reached $87 million, up 30% sequentially; full-year revenue totaled $264 million, with Amtagvi contributing $220 million (US) and Proleukin $44 million (global).

• Q4 gross margin improved to 50% from 43% in Q3, reflecting operational optimization and internalized manufacturing.

• Proleukin contributed about 17% of total revenue for 2025, with ordering patterns stabilizing.

• Cash position at year-end was $303 million, supporting operations into Q3 2027.

• Net loss for FY25 was $390.98 million; Q4 net loss was $71.9 million.

Outlook and guidance

• Expecting remarkable revenue growth in 2026, primarily from AMTAGVI, with formal guidance to be provided soon.

• Operational improvements and internalized manufacturing expected to further enhance margins and reduce costs in 2026–2027.

• Preparing for commercial launches in new indications, including non-small cell lung cancer and sarcoma, with potential U.S. launch for lung cancer in 2H 2027.

• Global expansion underway, with AMTAGVI approved in Canada and pending approvals in the U.K., Australia, and Switzerland.